Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COMMENTARY
Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
To read the full story
Related Article
- Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
October 11, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Panel Proposes Lifting Bans on Cannabis-Derived Drugs, Introducing Distribution Control
October 3, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- MHLW Panel Recommends Lifting Ban on Cannabis-Derived Drugs, Eyes Legal Amendment Next Spring
June 15, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
COMMENTARY
- Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
- Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
- TSE’s Growth Market Reform Puts Pressure on Biotechs
January 27, 2026
- Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
- Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…